quiz bu lëkkale ak tegtal · Diggante Niveau

AI in Lung Cancer Screening CT Quiz

Tests AI nodule support, screening versus diagnosis, FDA intended use, false-positive risks, radiologist review, and follow-up requirements.

Yooni njiit yu jëm ciAI In Lung Cancer Screening Ct
Laaj 1 de 8

What output is expected from the FDA-authorized lung CT CAD tool described here?

Xoolaatal laaj bu nekk8 laaj

Sooy def quiz bi, tontu yi ak leeral yi dañuy feeñ.

  1. What output is expected from the FDA-authorized lung CT CAD tool described here?
    • Decide who is eligible for screening
    • Replace follow-up imaging after a positive result
    • Highlight potential nodules for radiologist review
    • Diagnose lung cancer independently from the image
  2. How does screening CT differ from a diagnostic CT?
    • There is no difference in purpose
    • Screening is used for eligible people without symptoms; diagnostic imaging investigates a clinical concern
    • Screening is only performed after a nodule is confirmed
    • Diagnostic CT is always AI-read and screening is not
  3. What can a positive AI nodule mark mean?
    • A confirmed cancer diagnosis
    • Proof that the person must have surgery
    • Evidence that the nodule is malignant
    • A candidate finding for radiologist review that may lead to follow-up
  4. Why can an AI nodule tool produce false positives?
    • Normal structures or benign nodules may resemble the patterns it flags
    • The model reads the patient’s family history directly
    • The scanner automatically labels every nodule as cancer
    • Radiologists never compare prior images
  5. What should a radiologist do with a model-generated nodule mark?
    • Change the screening eligibility rules
    • Review it in the source CT with clinical context and prior images
    • Accept it automatically as a diagnosis
    • Ignore image quality and patient history
  6. Why validate AI performance on local scanners and populations?
    • Image protocols and patient populations can affect model performance
    • FDA authorization guarantees identical performance everywhere
    • Local validation changes the medical diagnosis
    • A different scanner cannot alter image quality
  7. Which screening harm should patients discuss with a clinician?
    • The guarantee that no cancer can be missed
    • An automatic treatment from the AI tool
    • The removal of all incidental findings
    • False positives and follow-up tests after an abnormal finding
  8. What does an AI result alone establish?
    • That cancer is present or absent with certainty
    • That follow-up is unnecessary
    • Only a software output that must be interpreted in the screening pathway
    • That the patient meets screening criteria